Multiple real-world studies show consistent high effectiveness of

多项真实世界研究表明其持续的高效性

Vocabria

卡博特韦

+

+

Rekambys

雷坎比斯

(cabotegravir + rilpivirine LA (CAB+RPV LA)) across a broad range of populations

（卡博特韦 + 利匹韦林长效制剂 (CAB+RPV LA)）覆盖广泛的人群范围

Implementation science data for

实施科学数据用于

Apretude

阿普雷特уд

(cabotegravir long-acting (CAB LA) for PrEP) demonstrate 95% of participants were happy they switched from oral PrEP to CAB LA

（卡博特韦长效注射剂 (CAB LA) 用于PrEP）显示95%的参与者对他们从口服PrEP转为CAB LA感到满意。

GSK plc (LSE/NYSE: GSK) announced ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today shared data from the phase IIIb VOLITION study demonstrating that 89% (n=129/145) of eligible treatment-naïve people living with HIV opted to switch to long-acting injectable .

GSK plc（LSE/NYSE：GSK）宣布，由GSK控股、辉瑞和盐野木为股东的全球HIV专业公司ViiV Healthcare今天分享了IIIb期VOLITION研究的数据，数据显示89%（n=129/145）符合条件的初治HIV感染者选择转用长效注射剂。

Vocabria

卡博特韦

+

加号

Rekambys

雷坎比斯

(branded as

（品牌为

Cabenuva

卡贝努瓦

in the US, Canada and Australia) following rapid viral suppression with daily

在美国、加拿大和澳大利亚）在每日快速病毒抑制之后

Dovato

多瓦托

(dolutegravir/lamivudine (DTG/3TC)). Additional real-world data from other studies reinforce CAB+RPV LA’s effectiveness across a broad range of populations.

（多替拉韦/拉米夫定 (DTG/3TC)）。其他研究的更多真实世界数据进一步证实了CAB+RPV LA在广泛人群中的有效性。

Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said:

ViiV Healthcare的首席医疗官Jean van Wyk（医学学士，药物流行病学硕士）表示：

“Data from the VOLITION study highlight how providing choice in HIV care empowers individuals to choose medicines that meet their evolving everyday needs. ViiV pioneered long-acting injectables for HIV, and we now have over three years of robust real-world evidence demonstrating the impact our portfolio is having today across a broad range of settings and populations.

“VOLITION研究的数据强调了在艾滋病护理中提供选择如何使个人能够选择符合他们不断变化的日常需求的药物。ViiV开创了用于艾滋病治疗的长效注射剂，如今我们已经积累了超过三年的坚实真实世界证据，证明了我们的产品组合在各种环境和人群中的实际影响。”

Long-acting injectables provide options that can offer high effectiveness and tolerability, improved adherence, and a preferred dosing schedule compared with daily oral pills. We believe they are a key part of HIV treatment and prevention and will play a critical role in achieving our ambition of ending HIV and AIDS.”.

长效注射剂提供了与每日口服药丸相比，具有高效性、耐受性、改善的依从性和更优的给药时间表的选择。我们相信它们是艾滋病治疗和预防的关键部分，并将在实现我们终结艾滋病的目标中发挥至关重要的作用。"

Data summary from ViiV Healthcare and partner studies at IAS 2025:

ViiV Healthcare及其合作伙伴在2025年IAS上的数据摘要：

Empowering choice: 89% of treatment-naïve people with HIV opt for CAB+RPV LA after achieving rapid viral suppression

赋予选择权：89% 的初治 HIV 感染者在实现快速病毒抑制后选择 CAB+RPV 长效方案

: These new data from the phase IIIb VOLITION study evaluate the experience of treatment-naïve individuals who initiated treatment with daily DTG/3TC pills and were subsequently offered the choice to switch to CAB+RPV LA after achieving viral suppression. Study results showed that participants achieved rapid viral suppression with DTG/3TC (median time to suppression: 4.14 weeks), following which they were offered to switch.

：这些来自 IIIb 期 VOLITION 研究的新数据评估了初次接受治疗的患者使用每日一次的 DTG/3TC 药片进行治疗并在实现病毒抑制后，随后被提供选择转换为 CAB+RPV 长效注射剂的体验。研究结果显示，参与者通过 DTG/3TC 实现了快速的病毒抑制（中位抑制时间：4.14 周），之后他们被提供转换选项。

At the immediate next study visit (Day of Choice), 89% (n=129/145) of eligible participants chose to switch to CAB+RPV LA, while 11% (n=16) opted to continue DTG/3TC. The most common reasons cited for choosing CAB+RPV LA were not having to worry about missing a dose each day (80%) and not having to carry medication (68%).

在紧接的下一次研究访视（选择日）时，89%（n=129/145）的符合条件的参与者选择改用CAB+RPV LA，而11%（n=16）选择继续使用DTG/3TC。选择CAB+RPV LA最常见的理由是不必担心每天忘记服药（80%）以及不用随身携带药物（68%）。

These findings underscore the efficacy and tolerability of DTG/3TC as a rapid suppression option, and demonstrate the value of offering CAB+RPV LA as a treatment option to meet individual needs and preferences.

这些研究结果强调了DTG/3TC作为快速抑制选项的有效性和耐受性，并展示了提供CAB+RPV LA作为一种治疗选择以满足个体需求和偏好的价值。

1.

1.

CAB+RPV LA delivers sustained effectiveness and enhanced patient experience in real-world settings:

CAB+RPV LA在真实世界环境中提供了持续的有效性和增强的患者体验：

Data from multiple real-world observational studies, including the two-year BEYOND study in the US, the CARLOS study in Germany, the COMBINE-2 cohort across seven European countries, and the OPERA study, consistently reinforce the high effectiveness, favourable outcomes and patient satisfaction associated with CAB+RPV LA.

来自多个真实世界观察性研究的数据，包括美国为期两年的BEYOND研究、德国的CARLOS研究、横跨七个欧洲国家的COMBINE-2队列以及OPERA研究，一致证实了CAB+RPV LA的高效性、良好结果和患者满意度。

2,3,4,5,6,7

2,3,4,5,6,7

.

。

BEYOND is a two-year prospective observational study enrolling people with HIV following the decision to switch to CAB+RPV LA across 27 US sites

BEYOND 是一项为期两年的前瞻性观察性研究，在美国 27 个研究中心招募决定改用 CAB+RPV LA 的 HIV 感染者。

2

2

. Among the 308 participants, 97% maintained virologic suppression at Month 24 (at most recent viral load of <50 copies/ml), with infrequent discontinuations due to injection reactions and no new confirmed virologic failures after Month 6. Participants reported reduced stigma and improved treatment satisfaction.

在308名参与者中，97%在第24个月时维持了病毒学抑制（最近一次病毒载量小于50拷贝/毫升），因注射反应而停药的情况很少，并且在第6个月后没有新的确认病毒学失败。参与者报告称感到羞辱感减轻，治疗满意度提高。

3

3

.

。

Similarly, the real-world CARLOS study of 351 participants in Germany, showed 77.5% virologic suppression at Month 24, with high adherence (94.2% on-time injections) and clinically meaningful improvements in treatment satisfaction

同样，德国针对351名参与者的真实世界CARLOS研究表明，第24个月时病毒学抑制率达到77.5%，同时保持高依从性（94.2%的注射按时进行）以及治疗满意度有临床意义上的提升。

4

4

. 97.7% of participants maintained virologic suppression at last known viral load at Month 24 or at discontinuation.

97.7%的参与者在第24个月或停止治疗时最后一次已知病毒载量保持了病毒学抑制。

In Europe, the COMBINE-2 study, evaluating real-world outcomes for 956 virologically suppressed people with HIV initiating CAB+RPV LA across seven European countries, reported 99% virologic suppression at last measured viral load (median follow-up of 10.2 months), with low rates of confirmed virologic failure (0.5%) and high persistence (92% remaining on therapy).

在欧洲，COMBINE-2 研究评估了来自七个欧洲国家的 956 名病毒学抑制的 HIV 感染者开始使用 CAB+RPV LA 的真实世界结果，报告显示在最后一次测量的病毒载量时，99% 的患者实现了病毒学抑制（中位随访时间为 10.2 个月），确认的病毒学失败率较低（0.5%），并且高持续性（92% 的患者继续接受治疗）。

5

5

.

。

Real-world evidence focussed on the effectiveness of CAB+RPV LA outside the labelled indication in viraemic patients

聚焦于CAB+RPV LA在病毒血症患者中标示外使用效果的真实世界证据

: The large-scale OPERA study further explored the effectiveness of CAB+RPV LA in treatment-experienced individuals initiating therapy with detectable viral loads and long-standing HIV. Among the 3,304 participants, 11% (368 individuals) initiated with baseline viremia (>50 copies/mL), of these, 88% achieved viral suppression to <50 copies/mL (of n=277/313 with ≥1 viral load during follow-up and VL <50 copies/mL at any point during follow-up).

大型OPERA研究进一步探讨了CAB+RPV LA在治疗经验丰富的个体中的有效性，这些个体在开始治疗时病毒载量可检测到且感染HIV已久。在3,304名参与者中，11%（368人）基线时存在病毒血症（>50拷贝/mL），其中88%的个体实现了病毒抑制至<50拷贝/mL（在随访期间有≥1次病毒载量测量且任意时间点病毒载量<50拷贝/mL的277/313人）。

A separate analysis also showed that among a diverse group of 105 women initiating CAB+RPV LA with viremia, most achieved viral suppression (of 92 women with ≥1 VL at follow-up, 92% achieved VL <50 copies/mL at any point during follow-up), with confirmed virologic failure being rare.

另一项独立分析还显示，在开始使用CAB+RPV LA的105名病毒血症女性的多样化群体中，大多数人实现了病毒抑制（在随访中有≥1次病毒载量检测的92名女性中，92%在随访期间的某个时间点达到了病毒载量<50拷贝/毫升），确认的病毒学失败很少见。

6,7

6,7

.

。

Through these findings, CAB+RPV LA was shown to address challenges associated with daily oral pills, offering improved treatment satisfaction, high effectiveness and a patient-preferred treatment option that supports long-term virologic control.

通过这些研究结果，CAB+RPV 长效制剂被证明能够应对与每日口服药片相关的问题，提供更高的治疗满意度、高效性以及患者偏好的治疗选择，有助于实现长期的病毒学控制。

Implementation studies highlight CAB LA for PrEP is highly preferred and easy to implement for key prevention groups:

实施研究强调，CAB LA 用于 PrEP 在关键预防群体中备受青睐且易于实施：

The PILLAR and EBONI studies highlight the high acceptability and feasibility of CAB LA for PrEP for HIV prevention in broad populations, including men who have sex with men (MSM), transgender men (TGM), and Black women (BW)

PILLAR 和 EBONI 研究强调了CAB LA在广泛人群中作为HIV预防的PrEP方案的高接受度和可行性，这些人群包括男男性行为者（MSM）、跨性别男性（TGM）以及黑人女性（BW）。

8,9

8,9

.

。

PILLAR is a phase IV implementation trial assessing the integration of CAB LA for PrEP across 17 clinics in the US among a broad population of MSM and TGM (n=201)

PILLAR 是一项 IV 期实施试验，评估在美国 17 家诊所中广泛 MSM 和 TGM 人群（n=201）中整合 CAB LA 用于 PrEP 的情况。

8

8

. CAB LA for PrEP was rated highly acceptable (mean 4.6/5 at Month 12) and feasible (mean 4.4/5), with 95% of participants (n=131) who switched from oral PrEP reporting being happy with the choice and 98% recommending CAB LA for PrEP (n=140). Flexible scheduling, reminders, and educational tools supported adherence, while stigma concerns were significantly lower compared to oral PrEP users..

CAB LA用于PrEP的接受度被评为很高（第12个月平均4.6/5），可行性也很高（平均4.4/5），95%从口服PrEP转为CAB LA的参与者（n=131）表示对这一选择感到满意，98%的人推荐使用CAB LA作为PrEP（n=140）。灵活的时间安排、提醒和教育工具帮助提高了依从性，而与口服PrEP用户相比，对污名化的担忧显著降低。

Similarly, EBONI, an implementation study evaluating CAB LA for PrEP in Black cis and transgender women, among women’s health clinics, across 72 healthcare provider respondents at 15 clinics primary care and infectious disease clinics in the US. Data found CAB LA for PrEP highly appropriate (mean 4.5/5) and feasible (mean 4.4/5) for Black women.

同样，EBONI 是一项评估 CAB LA 用于 PrEP 在黑人顺性别和跨性别女性中的实施研究，该研究在美国 15 家诊所的 72 名医疗保健提供者中进行，这些诊所包括妇产科诊所、初级保健和传染病诊所。数据显示，CAB LA 用于 PrEP 对于黑人女性而言非常合适（平均 4.5/5）且可行（平均 4.4/5）。

9

9

. In addition, clinic capacity to accommodate CAB LA for PrEP tripled within a year without increasing staff or time commitment. The health benefits of two monthly visits included additional opportunities to screen for STIs, screening for comorbidities or providing other health or psychological care..

此外，诊所容纳CAB LA进行PrEP的能力在一年内增加了两倍，而无需增加人员或时间投入。每月两次的就诊带来的健康益处包括更多筛查性传播感染的机会、筛查共病或提供其他健康或心理护理。

These findings highlight

这些发现突显了

Apretude

阿普雷特уд

’s potential to support broader PrEP implementation and improve outcomes in underserved populations who may benefit the most across varied clinical settings.

在可能受益最多的不同临床环境中，支持更广泛的PrEP实施并改善服务不足人群的结果的潜力。

About

关于

Apretude

阿普雷特уд

(cabotegravir long-acting for PrEP)

（长效卡博特韦用于PrEP）

Apretude

阿普雷曲尔

is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. Individuals must have a negative HIV-1 test prior to initiating

是一种用于预防性传播HIV-1感染（暴露前预防或PrEP）的药物，适用于体重至少35公斤且感染风险较高的成人和青少年。在开始使用之前，个体必须进行HIV-1阴性测试。

Apretude

阿普雷特уд

(with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. It should be used in combination with safer sex practices, such as using condoms.

（无论是否使用口服卡博特韦作为引导）用于HIV-1的PrEP。应与安全性行为实践结合使用，例如使用避孕套。

Apretude

阿普雷特уд

contains the active substance cabotegravir.

包含活性物质卡博特韦。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Apretude 600 mg prolonged-release suspension for injection

Apretude 600 mg 长效注射混悬液

About

关于

Vocabria

卡博特韦

(cabotegravir)

（卡博特韦）

Vocabria

卡博特韦

injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class..

注射剂与利匹韦林注射剂联合使用，用于治疗成年人和青少年（至少12岁且体重至少35公斤）的人类免疫缺陷病毒1型（HIV-1）感染，这些患者在稳定的抗逆转录病毒治疗方案下病毒学上受到抑制（HIV-1 RNA <50拷贝/毫升），没有当前或过去的证据显示对非核苷类逆转录酶抑制剂（NNRTI）和整合酶抑制剂（INI）类药物产生耐药性，且无既往病毒学失败史。

Vocabria

卡博特韦

tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:.

片剂与利匹韦林片剂联合使用，适用于短期治疗 HIV-1 感染的成人和青少年（至少 12 岁且体重至少 35 公斤），这些患者在稳定的抗逆转录病毒治疗方案下病毒学抑制良好（HIV-1 RNA <50 拷贝/mL），且目前或过去无对 NNRTI 和 INI 类药物的病毒耐药性证据，也未曾因使用这些药物而导致病毒学失败。

oral lead-in to assess tolerability of

口服导入以评估耐受性

Vocabria

卡博特韦

and rilpivirine prior to administration of long acting

以及在给予长效药物之前的利匹韦林

Vocabria

卡博特韦

injection plus long acting rilpivirine injection.

长效利匹韦林注射剂。

oral therapy for adults who will miss planned dosing with

成人计划剂量缺失时的口服治疗方案

Vocabria

Vocabria

injection plus rilpivirine injection.

注射加利匹韦林注射。

Vocabria

卡博特韦

tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for

片剂仅适用于与利匹韦林片剂联合治疗HIV-1，因此，处方信息为

Edurant

依度拉平

(rilpivirine) tablets should also be consulted for recommended dosing.

（利匹韦林）片剂也应咨询推荐的剂量。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Vocabria

vocabulary

400mg/600 mg prolonged-release suspension for injection and

400毫克/600毫克 长效注射用混悬液

Vocabria

Vocabria

30 mg film-coated tablets

30毫克薄膜衣片

About

关于

Rekambys (rilpivirine)

雷坎比斯（利匹韦林）

Rekambys

雷坎比斯

is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class..

与卡博特韦注射剂联合使用，用于治疗 HIV-1 感染的成人和青少年（至少 12 岁且体重至少 35 公斤），这些患者在稳定的抗逆转录病毒治疗方案下病毒学上得到抑制（HIV-1 RNA <50 拷贝/mL），且没有当前或过去的证据显示对 NNRTI 和 INI 类药物产生病毒耐药性，也没有在这类药物上出现过病毒学失败。

Rekambys

里卡姆比斯

should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing.

应始终与卡博特韦注射剂联合使用。应参阅卡博特韦注射剂的处方信息以获取推荐剂量。

Rekambys

里卡姆比斯

may be initiated with oral lead-in or without (direct to injection).

可以通过口服引导开始，也可以不通过口服直接注射。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Rekambys

雷坎比斯

600mg/900 mg prolonged-release suspension for injection

600毫克/900毫克 长效注射混悬液

About Cabenuva (cabotegravir + rilpivirine)

关于Cabenuva（卡博特韦+利匹韦林）

Cabenuva

卡贝努瓦

is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine..

被指定为用于治疗12岁及以上且体重至少35公斤的成人和青少年HIV-1感染的完整方案，用于替换当前的抗逆转录病毒方案，适用于那些在稳定的抗逆转录病毒治疗下病毒学上受到抑制（HIV-1 RNA <50拷贝/毫升）的患者，这些患者没有治疗失败的历史，且对卡博特韦或利匹韦林无已知或怀疑的耐药性。

The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland Unlimited Company. Rilpivirine tablets are approved in the US and when used with cabotegravir is indicated for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine..

完整的治疗方案结合了由ViiV Healthcare开发的整合酶链转移抑制剂（INSTI）卡博特韦和由Janssen Sciences Ireland Unlimited Company开发的非核苷逆转录酶抑制剂（NNRTI）利匹韦林。利匹韦林片在美国已获批准，与卡博特韦联合使用时，适用于短期治疗HIV-1感染，针对12岁及以上且体重至少35公斤的成人和青少年，这些患者在稳定的治疗方案下病毒学上受到抑制（HIV-1 RNA小于50拷贝/mL），无治疗失败史，并且对卡博特韦或利匹韦林均无已知或怀疑的耐药性。

INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse transcriptase, which stops the virus from multiplying..

整合酶抑制剂通过阻止病毒DNA整合到人体免疫细胞（T细胞）的遗传物质中来抑制HIV复制。这一步骤在HIV复制周期中至关重要，也是导致慢性疾病形成的关键。利匹韦林是一种非核苷类逆转录酶抑制剂，通过干扰一种名为逆转录酶的酶来发挥作用，从而阻止病毒增殖。

Please consult the full Prescribing Information

请查阅完整的处方信息

here

这里

About

关于

Dovato

多瓦托

(dolutegravir and lamivudine)

（多鲁特格拉韦和拉米夫定）

Dovato

多瓦托

is indicated as a complete regimen to treat HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25 kg in the US, with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of .

在欧盟，被推荐作为完整的治疗方案用于治疗12岁以上、体重至少40公斤的成人和青少年的HIV-1感染；在美国，适用于体重至少25公斤的患者。适用人群包括无抗逆转录病毒（ARV）治疗史的患者，或用于替换当前ARV治疗方案，且在稳定ARV治疗方案下病毒学抑制（HIV-1 RNA <50拷贝/mL）的患者，这些患者无治疗失败史且对任何组分无已知耐药性。

Dovato

多瓦托

.

。

Please consult the full Summary of Product Characteristics for all the safety information:

请查阅完整的产品特性摘要以获取所有安全信息：

Dovato

多瓦托

50 mg/300 mg film-coated tablets

50毫克/300毫克薄膜包衣片

.

。

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

商标由ViiV Healthcare集团的公司所有或授权使用。

About ViiV Healthcare

关于ViiV医疗保健

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012.

ViiV Healthcare 是一家全球专业的 HIV 公司，于 2009 年 11 月由葛兰素史克（GSK，伦敦证交所代码：GSK）和辉瑞（Pfizer，纽约证交所代码：PFE）创立，致力于为 HIV 感染者以及可能受益于 HIV 预防的人们提供治疗和护理的进展。盐野义制药于 2012 年 10 月成为 ViiV 的股东。

The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. .

该公司的目标是比任何公司都更深入、更广泛地关注艾滋病和艾滋病，并采取新的方法，为艾滋病的治疗和预防提供有效且创新的药物，同时支持受艾滋病影响的社区。如需了解更多关于该公司、其管理、产品组合、研发进展和承诺的信息，请访问 viivhealthcare.com。

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。

Cautionary statement regarding forward-looking statements

关于前瞻性声明的谨慎声明

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q1 Results for 2025..

GSK提醒投资者，GSK所做出的任何前瞻性声明或预测，包括本公告中包含的内容，均受可能致使实际结果与预测结果存在重大差异的风险和不确定性影响。这些因素包括但不限于GSK 2024年Form 20-F年度报告中“风险因素”部分以及GSK 2025年第一季度业绩报告中描述的内容。

References

参考文献

F. Felizarta, et al. The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in treatment naive people living with HIV. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

F. Felizarta 等。选择的力量：在初治 HIV 感染者中，使用 DTG/3TC 快速抑制后，对 CAB+RPV 长效方案的强烈偏好。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

F. Felizarta, et al. Perspectives of people living with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

F. Felizarta 等。在美国一项观察性真实世界研究（BEYOND）中，HIV感染者（PWH）在转用卡博特韦和利匹韦林长效注射剂（CAB+RPV LA）24个月后的看法。于2025年7月13-17日，在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

G. Blick, et al. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

G. Blick 等。在一项观察性真实世界研究（BEYOND）中，开始使用卡博特韦和利匹韦林长效制剂（CAB+RPV LA）后第24个月的临床结果。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

C. Wyen, et al. 24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real‑world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW..

C. Wyen 等人。在真实世界环境中每2个月使用卡博特韦+利匹韦林长效注射剂的24个月结果：来自德国CARLOS队列中HIV-1感染者的有效性、注射依从性及参与者报告的结果。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

A. Pozniak, et al. High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW..

A. Pozniak 等。在欧洲 COMBINE-2 队列中，接受长效卡博特韦和利匹韦林治疗的经验丰富的病毒学抑制个体表现出高病毒学抑制率和极少的病毒学失败。于 2025 年 7 月 13 日至 17 日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

R. Hsu, et al. Real-world effectiveness of CAB+RPV LA in individuals with HIV viremia at therapy initiation. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

R. Hsu 等人。CAB+RPV 长效制剂在治疗开始时携带HIV病毒血症个体中的真实世界有效性。于2025年7月13日至17日在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

J. Altamirano, et al. Clinical outcomes among women in the OPERA cohort initiating CAB+RPV LA with viral loads ≥ 50 copies/mL. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

J. Altamirano 等。OPERA 队列中开始使用 CAB+RPV LA 且病毒载量 ≥ 50 拷贝/mL 的女性的临床结果。于 2025 年 7 月 13-17 日在卢旺达基加利举行的国际艾滋病学会会议 (IAS 2025) 上发表。

D. Dandachi, et al. One-year implementation outcomes of cabotegravir long-acting injectable PrEP in men who have sex with men (MSM) & transgender men (TGM): findings from the PILLAR study. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

D. Dandachi 等人。长效注射型卡博特韦预防药物在男男性行为者（MSM）及跨性别男性（TGM）中实施一年的成果：来自PILLAR研究的发现。于2025年7月13日至17日，在卢旺达基加利举行的国际艾滋病学会会议（IAS 2025）上发表。

Z. Tims-Cook, et al. Health care provider experiences after 12 months of implementing cabotegravir long-acting injectable PrEP (CAB LA) for Black women: EBONI study results. Presented at the International AIDS Society Conference (IAS 2025), 13-17 July, Kigali, RW.

Z. Tims-Cook 等。实施卡博特韦长效注射PrEP（CAB LA）12个月后医疗保健提供者的经验：EBONI研究结果。在国际艾滋病学会会议（IAS 2025）上发表，2025年7月13-17日，卢旺达基加利。